The combination of lenvatinib (Lenvima) and pembrolizumab (Keytruda) plus chemotherapy failed to improve overall survival (OS) vs pembrolizumab plus chemotherapy alone as frontline treatment in patients with metastatic esophageal squamous cell…
Lenvatinib Plus Pembrolizumab and Chemotherapy Fails to Improve OS in Advanced ESCC
